

StemRIM Announces Fixed Details of the Issuance of Stock Options to Temporary Employees and External Collaborator

Osaka, Japan, September 26, 2025 – StemRIM Inc. (TSE: 4599, President and CEO: Masatsune Okajima; “StemRIM”) announces that fixed details issuance 17th Stock Acquisition Rights (b) of StemRIM (“Stock Option”) to temporary employees and external collaborator based on the board of directors' meeting held on September 10, 2025.

17th Stock Acquisition Rights (b) of StemRIM

1. Total number of Stock Option	370 units				
2. Type and number of shares	37,000 shares of common stock, 100 shares per unit				
3. Exercise price	31,100 yen per unit, 311 yen per shares				
4. Persons to whom stock acquisition rights are to be allocated, their number, and the number of stock acquisition rights to be allotted	<table> <tr> <td>Temporary Employees</td><td>5</td></tr> <tr> <td>External Collaborator</td><td>1</td></tr> </table>	Temporary Employees	5	External Collaborator	1
Temporary Employees	5				
External Collaborator	1				

(Reference)StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Temporary Employees and External Collaborator, Dated September 10, 2025

About StemRIM Inc.

StemRIM Inc. is a biotech venture which began at Osaka University with the goal of realizing a new type of medicine called "Regeneration-Inducing Medicine™". The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. "Regeneration-Inducing Medicine™" is aimed at maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration. Certain disease areas expected to benefit from "Regeneration-Inducing Medicine™" include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH),

systemic sclerosis, and any other areas where treatment with extrapulmonary mesenchymal stem cells is promising.

Inquiries:

StemRIM Inc.

Management & Administrator Dept.

E-Mail: stemrim-ir@stemrim.com

X: [@StemRIM Inc](#)

For more information, please visit the StemRIM website (<https://stemrim.com/english/>)